Abeona Therapeutics Inc. (NASDAQ:ABEO) Q2 2023 Results Conference Call August 8, 2023 8:30 AM ET

Company Participants

Greg Gin - Vice President of Investor Relations and Corporate Communications

Vish Seshadri - Chief Executive Officer

Joe Vazzano - Chief Financial Officer

Madhav Vasanthavada - Vice President, Business Development

Brian Kevany - Chief Technical Officer

Conference Call Participants

Maury Raycroft - Jefferies

Kristen Kluska - Cantor Fitzgerald

David Bautz - Zacks Small Capital Research

Operator

Good day, and welcome to the Abeona Therapeutics Second Quarter 2023 Update Conference Call [Operator Instructions]. As a reminder, today's conference is being recorded.

I'll now introduce your host for today's conference, Greg Gin, Vice President of Investor Relations and Corporate Communications at Abeona. Sir, please go ahead.

Greg Gin

Thank you, operator, and good morning, everyone. I would like to welcome and thank everyone for joining us on our second quarter 2023 update conference call. The press release announcing the results is available on our Web site at www.abeonatherapeutics.com. Before we start, I would like to note that remarks made during today's call may contain projections and forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of the federal securities laws. These forward-looking statements are based on current expectations and are subject to change, and actual results may differ materially from those expressed or implied in the forward-looking statements. Various factors that could cause actual results to differ include, but are not limited to, those identified under the Risk Factors section in our Form 10-K and periodic reports filed with the SEC. These documents are available on our Web site at www.abeonatherapeutics.com. On the call today with prepared remarks are Dr. Vish Seshadri, Chief Executive Officer; and Joe Vazzano, Chief Financial Officer. Joining us for the Q&A session will be Dr. Madhav Vasanthavada, Vice President, Business Development; and Dr. Brian Kevany, Chief Technical Officer.

With that, I will now turn the call over to Vish Seshadri to lead us off. Vish?

Vish Seshadri

Thank you, Greg. Hello, everybody, and thank you for joining us this morning. We are happy to update you on our continued progress, in particular with our lead program, EB-101, our investigational autologous engineered cell therapy had to deliver years of sustained clinical benefit in patients with recessive dystrophic epidermolysis bullosa, or RDEB, in short. Remember that all our clinical data pertain to treatment of large chronic booms, which are the hardest to treat and have remained open for years because they cannot sell to you and inflict the great [Indiscernible] burden to these patients. The durability of both investigator-assessed [hemin] and patient-reported pain following a single administration of serving toughest RDEB wounds paints a very compelling and unique value proposition for EB-101 for patients. We have made significant progress during the last quarter towards planned EB-101 BLA submission. We have completed process performance qualification, or PPQ manufacturing runs for both retroviral vector and EB-101 drug product to demonstrate our validated process and readiness for commercial production.